AGPAT5 Mouse Monoclonal Antibody (Biotin conjugated) [Clone ID: OTI4H3]

CAT#: TA504145AM

AGPAT5 mouse monoclonal antibody, clone OTI4H3 (formerly 4H3), Biotinylated

Conjugation: Unconjugated Biotin HRP



  View other "OTI4H3" antibodies (4)

Need it in bulk or conjugated?
Get a free quote

CNY 3,990.00


货期*
2周

规格
    • 100 ul

Product images

经常一起买 (3)
beta Actin Mouse Monoclonal Antibody, Clone OTI1, Loading Control
    • 30 ul

CNY 300.00
CNY 1,430.00


Recombinant protein of human 1-acylglycerol-3-phosphate O-acyltransferase 5 (lysophosphatidic acid acyltransferase, epsilon) (AGPAT5), 20 µg
    • 20 ug

CNY 2,900.00
CNY 6,650.00


Transient overexpression lysate of 1-acylglycerol-3-phosphate O-acyltransferase 5 (lysophosphatidic acid acyltransferase, epsilon) (AGPAT5)
    • 100 ug

CNY 3,080.00

Specifications

Product Data
Clone Name OTI4H3
Applications WB
Recommend Dilution WB 1:2000
Reactivity Human
Host Mouse
Clonality Monoclonal
Immunogen Full length human recombinant protein of human AGPAT5(NP_060831) produced in HEK293T cell.
Formulation PBS (pH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide.
Concentration 0.5 mg/ml
Purification Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G)
Conjugation Biotin
Storage Condition Store at -20°C as received.
Predicted Protein Size 41.9 kDa
Gene Name 1-acylglycerol-3-phosphate O-acyltransferase 5
Background This gene encodes a member of the 1-acylglycerol-3-phosphate O-acyltransferase family. This integral membrane protein converts lysophosphatidic acid to phosphatidic acid, the second step in de novo phospholipid biosynthesis. [provided by RefSeq]. COMPLETENESS: complete on the 3' end.
Synonyms 1AGPAT5; LPAATE
Reference Data
Protein Families Transmembrane
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Other Versions

Customer Reviews 
Loading...